Valuation conundrum of healthcare-related stocks in US and M’sia


THE United States, which is the epicentre of the Covid-19 pandemic, is the base for some of the world’s largest healthcare companies. These companies are in the race to find a vaccine for the virus and have from time to time disclosed the progress of finding a wonder drug to prevent the spread of the virus.

However, the valuations of the more established pharmaceutical companies have remained sober even though the companies are in the forefront of the search to find a vaccine.

The Star Festive Promo: Get 35% OFF Digital Access

Monthly Plan

RM 13.90/month

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Ringgit likely to trade cautiously next week ahead of key US data
Powering a new reinvestment cycle as demand surges
Up in Arms - or up the value chain?
Asia bonds for diversification
Singapore’s financial sector a big winner
Smart city can’t beat the traffic
AI disruption fears rock markets
Private equity hits a sixer
Dubai luxe property keeps booming
US LNG exporters lead in gas use

Others Also Read